ArticleNPJ precision oncology2026

Lorlatinib monotherapy or combination therapy in anaplastic lymphoma kinase-driven high-risk neuroblastoma.

Weiji Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.